P/B
0,2
Aprea Therapeutics
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
$9.2M
Market Cap • 9/22/2026
2019
(7 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1778,5
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,9
EPS
—
Market Cap
Market Cap
9,2M
EV
-31,3M
EV/Revenue
-6033,6
EV/EBITDA
2,4
EV/EBIT
2,4
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-435,8%
Total Yield
-435,8%
Payout
0%
Retained Earnings
-340,5M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
129623%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,2%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
-22,3%
CAGR Net Income 5Y
-23,3%
CAGR EPS 5Y
-52,6%
CAGR OCF 5Y
-22,6%
Leverage
N.D./EBITDA
3,1
Debt/Equity
0%
Current Ratio
13,6
Quick Ratio
13,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!